Sterling Capital Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.9K Sell
216
-410
-65% -$44.1K ﹤0.01% 2087
2026
Q2
$54.4K Sell
626
-47
-7% -$2.84K ﹤0.01% 1564
2026
Q1
$27.1K Hold
673
– – ﹤0.01% 1882
2025
Q4
$23.4K Buy
673
+530
+371% +$41.6K ﹤0.01% 2140
2025
Q3
$11.9K Sell
143
-1
-0.7% -$72 ﹤0.01% 2395
2025
Q2
$10.6K Buy
144
+59
+69% +$4.28K ﹤0.01% 2099
2025
Q1
$9.7K Buy
85
+2
+2% +$122 ﹤0.01% 1872
2024
Q4
$4.18K Hold
83
– – ﹤0.01% 2538
2024
Q3
$3.84K Buy
+83
New +$2.95K ﹤0.01% 1862
2019
Q3
$1.17M Buy
+82,895
New +$1.02M 0.01% 553

Other funds holding CORT

Sterling Capital Management's CORT Position: Q3 2026 in Review

Sterling Capital Management reduced its Corcept Therapeutics (CORT) stake by 65% in Q3 2026, selling an estimated $44.1K and leaving 216 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Sterling Capital Management first reported a position in CORT in Q3 2019 and has held it in 10 quarters since. The position peaked at $1.17M in Q3 2019. 503 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Sterling Capital Management held 216 shares of Corcept Therapeutics worth $24.9K as of Q3 2026.
  • Sterling Capital Management sold 410 Corcept Therapeutics shares in Q3 2026, an estimated $44.1K.
  • Corcept Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2087 holding.
  • Sterling Capital Management first reported a position in Corcept Therapeutics in Q3 2019 and has held it in 10 quarters since.
  • Sterling Capital Management's Corcept Therapeutics position peaked at $1.17M in Q3 2019.
  • 503 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.